Oddo BHF Asset Management Sas Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Oddo BHF Asset Management Sas purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,695 shares of the medical research company’s stock, valued at approximately $2,771,000.

Several other institutional investors have also modified their holdings of the company. First Foundation Advisors grew its position in IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after purchasing an additional 43 shares during the last quarter. Invera Wealth Advisors LLC increased its position in IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares during the period. Private Trust Co. NA raised its stake in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares in the last quarter. Finally, Continuum Advisory LLC increased its holdings in shares of IQVIA by 3.3% during the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after purchasing an additional 49 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of several research analyst reports. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Wednesday. BTIG Research cut their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $256.19.

IQVIA Stock Down 0.7 %

IQV stock opened at $199.06 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $36.13 billion, a P/E ratio of 26.12, a P/E/G ratio of 2.07 and a beta of 1.49. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company’s 50 day simple moving average is $212.24 and its 200-day simple moving average is $224.23.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.